June 21, 2023 11:28 AM EDT
R&D

Trail­ing Akero and 89bio, Boston Phar­ma­ceu­ti­cals posts ear­ly da­ta on its NASH in­jec­tion

Lei Lei Wu

News Reporter

In an ear­ly-stage study, Boston Phar­ma­ceu­ti­cals’ in­jec­tion re­duced in­di­ca­tors of NASH, a fat­ty liv­er dis­ease. The treat­ment is one of a hand­ful of in­ves­ti­ga­tion­al drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times